Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML
Status:
Terminated
Trial end date:
2017-04-22
Target enrollment:
Participant gender:
Summary
The trial investigates the efficacy of adoptive immunotherapy with haploidentical natural
killer cells compared to standard chemotherapy (after first complete remission) in patients
with a high-risk acute myeloid leukemia being older than 65 years of age and not eligible for
allogeneic transplantation